Jianying Zhang1, Feng Li1, Daibang Nie1,2, Kentaro Onishi3, MaCalus V Hogan4, James H-C Wang4. 1. MechanoBiology Laboratory, Department of Orthopaedic Surgery, University of Pittsburgh, Pittsburgh, PA, USA. 2. Department of Immunology, College of Basic Medicine, Chongqing Medical University, Chongqing, China. 3. Department of Physical Medicine and Rehabilitation, University of Pittsburgh, Pittsburgh, PA, USA. 4. Departments of Orthopaedic Surgery, Bioengineering, and Physical Medicine and Rehabilitation, University of Pittsburgh, Pittsburgh, PA, USA.
Abstract
BACKGROUND: Tendinopathy is a debilitating tendon disorder that affects millions of Americans and costs billions of health care dollars every year. High mobility group box 1 (HMGB1), a known tissue damage signaling molecule, has been identified as a mediator in the development of tendinopathy due to mechanical overloading of tendons in mice. Metformin (Met), a drug approved by the Food and Drug Administration used for the treatment of type 2 diabetes, specifically inhibits HMGB1. This study tested the hypothesis that Met would prevent mechanical overloading-induced tendinopathy in a mouse model of tendinopathy created by intensive treadmill running (ITR). METHODS: C57BL/6J mice (female, 3 months old) were equally separated into 4 groups and treated for 24 weeks as follows: group 1 had cage control activities, group 2 received a single intraperitoneal injection of Met (50 mg/kg body weight) daily, group 3 underwent ITR to induce tendinopathy, and group 4 received daily Met injection along with ITR to inhibit HMGB1. Tendinopathic changes were assessed in Achilles tendons of all mice using histology, immunohistochemistry, and enzyme-linked immunosorbent assays. RESULTS: ITR induced HMGB1 release into the tendon matrix and developed characteristics of tendinopathy as evidenced by the expression of macrophage marker CD68, proinflammatory molecules (COX-2, PGE2), cell morphological changes from normal elongated cells to round cells, high levels of expression of chondrogenic markers (SOX-9, collagen type II), and accumulation of proteoglycans in tendinopathic tendons. Daily injection of Met inhibited HMGB1 release and decreased these degenerative changes in ITR tendons. CONCLUSIONS: Inhibition of HMGB1 by injections of Met prevented tendinopathy development due to mechanical overloading in the Achilles tendon in mice. CLINICAL RELEVANCE: Met may be able to be repurposed as a therapeutic option for preventing the development of tendinopathy in high-risk patients.
BACKGROUND:Tendinopathy is a debilitating tendon disorder that affects millions of Americans and costs billions of health care dollars every year. High mobility group box 1 (HMGB1), a known tissue damage signaling molecule, has been identified as a mediator in the development of tendinopathy due to mechanical overloading of tendons in mice. Metformin (Met), a drug approved by the Food and Drug Administration used for the treatment of type 2 diabetes, specifically inhibits HMGB1. This study tested the hypothesis that Met would prevent mechanical overloading-induced tendinopathy in a mouse model of tendinopathy created by intensive treadmill running (ITR). METHODS: C57BL/6J mice (female, 3 months old) were equally separated into 4 groups and treated for 24 weeks as follows: group 1 had cage control activities, group 2 received a single intraperitoneal injection of Met (50 mg/kg body weight) daily, group 3 underwent ITR to induce tendinopathy, and group 4 received daily Met injection along with ITR to inhibit HMGB1. Tendinopathic changes were assessed in Achilles tendons of all mice using histology, immunohistochemistry, and enzyme-linked immunosorbent assays. RESULTS: ITR induced HMGB1 release into the tendon matrix and developed characteristics of tendinopathy as evidenced by the expression of macrophage marker CD68, proinflammatory molecules (COX-2, PGE2), cell morphological changes from normal elongated cells to round cells, high levels of expression of chondrogenic markers (SOX-9, collagen type II), and accumulation of proteoglycans in tendinopathic tendons. Daily injection of Met inhibited HMGB1 release and decreased these degenerative changes in ITR tendons. CONCLUSIONS: Inhibition of HMGB1 by injections of Met prevented tendinopathy development due to mechanical overloading in the Achilles tendon in mice. CLINICAL RELEVANCE: Met may be able to be repurposed as a therapeutic option for preventing the development of tendinopathy in high-risk patients.
Authors: Moeed Akbar; Derek S Gilchrist; Susan M Kitson; Briana Nelis; Lindsay A N Crowe; Emma Garcia-Melchor; James H Reilly; Shauna C Kerr; George A C Murrell; Iain B McInnes; Neal L Millar Journal: RMD Open Date: 2017-07-28
Authors: Stephanie Georgina Dakin; Julia Newton; Fernando O Martinez; Robert Hedley; Stephen Gwilym; Natasha Jones; Hamish A B Reid; Simon Wood; Graham Wells; Louise Appleton; Kim Wheway; Bridget Watkins; Andrew Jonathan Carr Journal: Br J Sports Med Date: 2017-11-08 Impact factor: 13.800
Authors: Finosh G Thankam; Zachary K Roesch; Matthew F Dilisio; Mohamed M Radwan; Anuradha Kovilam; R Michael Gross; Devendra K Agrawal Journal: Sci Rep Date: 2018-06-11 Impact factor: 4.379